U.S. Energy Boom Ke...
Health Care: Drugs
Telik Inc. (TELK: NASDAQ)
$1.32 0.00 | 0.00%
05/23/13 - 03:59 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| TELK | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -16.26 | -68.94 | -95.36 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | |
| Net Income | 0.00 | 0.00 | |
| EPS | -0.72 | 0.00 |
Earnings for TELK:
| EBITDA | -7.00 |
| REVENUE | 0.00 |
Average Earnings Estimates
| Qtr (06/12) | Qtr (09/12) | FY (12/12) | FY (12/13) | |
|---|---|---|---|---|
| Average Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Number of Analysts | 0 | 0 | 0 | 0 |
| High Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Low Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Prior Year | $-1.80 | $-1.50 | $-6.61 | $n.a. |
| Growth Rate (Year over Year) | n.a.% | n.a.% | n.a.% | n.a.% |
Portfolios with TELK
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- UserASCO 2010
- UserASCO 2009 Nymph's Watch List.
- UserPeter J. Lotti Portfolio 1
- UserPete'spicks
- ContributorBarron's Activist Stocks 11...
- ContributorBarron's Activist Stocks 11...
- UserC070707
- Usergonzomoney
Latest TELK Headlines from TheStreet
- Icahn Should Hang It Up: Activist 10.28.09 | 06:10 am
- Insider Sells $20.2 Million of National Semi 01.16.09 | 09:01 am
- Insider Sells $1.2M of Noven Pharmaceuticals 01.06.09 | 09:01 am
- Feuerstein's Biotech-Stock Mailbag 04.05.08 | 11:04 am
- Feuerstein's Biotech-Stock Mailbag 11.03.07 | 11:11 am
- Monday's Health Winners & Losers 10.15.07 | 04:10 pm
- Feuerstein's Biotech-Stock Mailbag 09.29.07 | 11:09 am
- Telik Fails Ethics Test 08.09.07 | 08:08 am
- These Homebuilder Stocks Could Soar 07.13.07 | 08:07 am
- Stockpickr: How to Trade Like Carl Icahn 06.20.07 | 12:06 am
Press Releases for TELK
- Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome - PR Newswire 01.22.13 | 05:01 pm
- Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic Syndrome - PR Newswire 01.11.13 | 07:01 pm
- Telik Announces Telintra® Clinical Publication At The 54th Annual Meeting Of The American Society Of Hematology - PR Newswire 12.12.12 | 04:12 pm
- Telik Announces The Publication Of Two Reports In The Journal Of Hematology & Oncology Describing The Results Of A Clinical Study Of Telintra® In Combination With Revlimid® And A Genomic Study Designed To Identify Genes That Predict Response To Telintra In Patients With Myelodysplastic Syndrome - PR Newswire 05.15.12 | 06:05 am
- Telik Regains Compliance With Minimum Bid Price Requirement - PR Newswire 04.17.12 | 04:04 pm
- Telik Announces Reverse Split Of Common Stock - PR Newswire 03.30.12 | 01:03 pm
- Telik Announces Expansion Of Phase 2 Trial Of Telcyta In Hematologic Malignancies - PR Newswire 02.21.12 | 09:02 am
- Telik Announces Presentation And Webcast At 14th Annual BIO CEO & Investor Conference - PR Newswire 02.08.12 | 09:02 am
- Telik Announces Presentation And Webcast At 5th Annual OneMedForum Conference - PR Newswire 01.04.12 | 09:01 am
- Telik Announces The Results Of Genetic Signature Studies Of Myelodysplastic Syndrome Patients Likely To Respond To Telintra® (Ezatiostat Hydrochloride, TLK199) At The Annual Meeting Of The American Society Of Hematology - PR Newswire 12.13.11 | 09:12 am
Partner Headlines for TELK
- 5 Stocks Trading Below Net Cash - Part VI - Seeking Alpha 08.28.12 | 09:08 am
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
